#1 Clinical Trials Search in Europe

Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • A Phase I/II Study of GVV858 Alone or in Drug Combination for Patients with Advanced Hormone Receptor‑Positive, HER2‑Negative Breast Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia Denmark France Germany Italy Spain

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Italy The Netherlands Spain

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Greece Ireland Italy Poland +1

  • Study of elacestrant and exemestane treatment for patients with previously treated hormone receptor-positive, HER2-negative metastatic breast cancer with FES-avid lesions

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy

  • Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    France Germany Greece Hungary Italy Poland +1

  • Study of ECI830, ribociclib, and fulvestrant in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Czechia Denmark France Germany Italy Spain

  • Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Bulgaria Czechia Finland France Germany +8

  • Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Preoperative Elacestrant and PULSAR Adaptive Radiotherapy for Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Study for Patients with Stage II-III Disease

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Italy